- Home
- Products
- Customized ADCs
- TPBG
- Anti-TPBG ( L443C)-Mc-MMAD ADC
Anti-TPBG ( L443C)-Mc-MMAD ADC (CAT#: ADC-W-162)
This ADC product is comprised of an anti-TPBG monoclonal antibody (L443C) conjugated via a Mc linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- TPBG
- Alternative Names
- M6P1; TPBGAG; WAIF1; TPBG oncofetal antigen; TPBG oncotrophoblast glycoprotein; wnt-activated inhibitory factor 1; TPBG oncofetal trophoblast glycoprotein;
- Target Entrez Gene ID
- 7162
- Target UniProt ID
- Q13641
- Overview
- This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5 UTR results in multiple transcript variants that encode the same protein.
- Overview
- Engineered Anti-TPBG antibody, L443C
- Generic name
- L443C
- Species Reactivity
- Human
- Name
- Mc (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAD (monomethyl auristatin D)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNF (Afelimomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1853)
- Anti-FOLH1 (Capromab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1163)
- Anti-TGFB1 (Fresolimumab)-SPDB-DM4 ADC (CAT#: ADC-W-1797)
- Anti-IGF1R (Cixutumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1249)
- Anti-IL13 (Lebrikizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1309)
- Anti-CD40 (Dacetuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-900)
- Anti-CD79B (Polatuzumab )-SMCC-DM1 ADC (CAT#: ADC-W-2554)
- Anti-Phosphatidylserine (Sevirumab)-SPDB-DM4 ADC (CAT#: ADC-W-1983)
- Anti-CD74 (011 (B))-Mc-MMAF ADC (CAT#: ADC-W-039)
- Anti-CD3E (Otelixizumab)-SPDB-DM4 ADC (CAT#: ADC-W-2475)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-162. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-312 | Anti-TPBG (clone A1)-hydroxyl amino PEG-MMAD ADC | hydroxyl amino PEG linker | MMAD (monomethyl auristatin D) |
| ADC-W-161 | Anti-TPBG ( V422C)-Mc-MMAD ADC | Mc (maleimidocaproyl) | MMAD (monomethyl auristatin D) |
| ADC-W-197 | Anti-TPBG (clone H8)-AcBut-CalichDMH ADC | AcBut (4-(4'acetylphenoxy)butanoic acid) | CalichDMH (Calicheamicin (CM)) |
| ADC-W-165 | Anti-TPBG (L398C)-VC-MMAD ADC | VC (valine-citrulline) | MMAD (monomethyl auristatin D) |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-632 | Anti-ERBB2 (trastuzumab)-Aminocaproyl-MMAD ADC | Aminocaproyl | MMAD (monomethyl auristatin D) |
| ADC-W-167 | Anti-TPBG (L443C)-VC-MMAD ADC | VC (valine-citrulline) | MMAD (monomethyl auristatin D) |
| ADC-W-292 | Anti-TACSTD2 (clone 7E6)-PEG6-MMAD ADC | PEG6 ((Propylene Glycol)-6-propionyl) | MMAD (monomethyl auristatin D) |
| ADC-W-166 | Anti-TPBG (V422C)-VC-MMAD ADC | VC (valine-citrulline) | MMAD (monomethyl auristatin D) |
| ADC-W-634 | Anti-ERBB2 (trastuzumab)-AcLys-β-Ala-MMAD ADC | AcLys-β-ala | MMAD (monomethyl auristatin D) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
